<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385043</url>
  </required_header>
  <id_info>
    <org_study_id>Covid-19 convalescent plasma</org_study_id>
    <nct_id>NCT04385043</nct_id>
  </id_info>
  <brief_title>Hyperimmune Plasma in Patients With COVID-19 Severe Infection</brief_title>
  <acronym>COV2-CP</acronym>
  <official_title>Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Sanitaria Provinciale Di Catanzaro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Annunziata Hospital, Cosenza, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Bianchi-Melacrino-Morelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Catanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma
      - or &quot;hyperimmune&quot; plasma was one of the most widespread and effective anti-infective
      treatments in the pre-antibiotic era and one of the founding pillars of immunology, and has
      also been used during the SARS (2002-2003) and Ebola (2014-2016) viral epidemy for which
      there were no alternative immunoprophylactic or therapeutic interventions.

      To date, there are not proven etiological therapies for SARS-CoV-2 infection, the agent
      responsible for the disease called Covid-19. Among those subjected to clinical studies during
      the current epidemic in China, hyperimmune plasma appears to be one of the most rational and
      promising.

      The objective of this study will be to evaluate the efficacy and safety of the hyperimmune
      plasma administered add-on to the anti-Covid-19 treatment (standard therapy) according to
      clinical practice in patients with severe Covid-19 infection, compared to patients with
      severe Covid-19 infection treated only with standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma
      - or &quot;hyperimmune&quot; plasma was one of the most widespread and effective anti-infective
      treatments in the pre-antibiotic era and one of the founding pillars of immunology.
      Immunoprophylaxis represents an irreplaceable protection for post-exposure prevention of
      several viral infections such as measles, hepatitis B and rabies. Recently, the use of
      convalescent plasma for therapeutic purposes has been re-evaluated during the SARS
      (2002-2003) and Ebola (2014-2016) epidemic caused by serious viral infections for which there
      were no immunoprophylactic or therapeutic interventions. alternative. The results of these
      experimental interventions, despite the limited number and the often anecdotal character,
      have shown promise even if not conclusive. In the case of SARS, the first human respiratory
      disease caused by a Coronavirus, treatment with convalescent plasma was associated with a 23%
      reduction in mortality and with the best results if administered at an early stage of the
      disease. In addition, all the evidence available in the literature has confirmed the safety
      of convalescent plasma treatments, in line with what has already been observed in the
      transfusion practice with Fresh Frozen Plasma.

      As is known, there are currently no proven etiological therapies to combat SARS-CoV-2
      infection, the agent responsible for the disease called Covid-19. Among those subjected to
      clinical studies during the current epidemic in China, hyperimmune plasma appears to be one
      of the most rational and promising.

      Waiting for the numerous clinical trials underway especially in Asia and accessible on the
      website http://apps.who.int/trialsearch/default.aspx to define if and to what extent this
      therapeutic contribution improves the prognosis of patients suffering from serious forms of
      infections from SARS-Co-2, the clinical guidelines of the People's Republic of China, already
      provide for the use of hyperimmune plasma with the indication &quot;in rapidly progressive
      disease, severe and very severe form&quot; and by the FDA .

      As regards the technical protocols for the preparation of hyperimmune plasma for clinical use
      in the literature, precise references are available in particular for the preparation,
      qualification, viral inactivation and dosage of hyperimmune plasma for the treatment of viral
      epidemic infections such as MERS and Ebola and which can also be validated and used for the
      preparation of plasma from convalescent patients for Covid-19.

      From the above, the objective of this study will be to evaluate the efficacy and safety of
      the hyperimmune plasma administered add-on to the anti-Covid-19 treatment (standard therapy)
      according to clinical practice in patients with severe Covid-19 infection, compared to
      patients with severe Covid-19 infection treated only with standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Statistically significant reduction (P &lt;0.05) of mortality in the group of patients treated with hyperimmune plasma vs patients treated with standard therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lymphocytes</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Statistically significant increase (P &lt;0.05) of lymphocyte levels after 7 and 14 days after the start of treatment with hyperimmune plasma (treated group), compared to the control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR levels vs control</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Statistically significant reduction (P &lt;0.05) of plasma levels of reactive protein C (expressed as mg/L), 7 and 14 days after the start of treatment with hyperimmune plasma vs standard therapy (group control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR levels vs before treatment</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Statistically significant reduction (P &lt;0.05) of plasma levels of reactive protein C (expressed as mg/L), 7 and 14 days after the start of treatment with hyperimmune plasma vs the same patients before the beginning of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AB levels and clinical improvement</measure>
    <time_frame>30 days</time_frame>
    <description>Significant Correlation (P&lt;0.05) between hyperimmune plasma antibody levels and clinical improvement time (expressed in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines vs controls</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Statistically significant reduction (P &lt;0.05) of plasma levels of IL-6 (expressed as pg/mL) and TNF-alpha (expressed as pg/mL), 7 and 14 days after the start of treatment with hyperimmune plasma vs standard therapy (group control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines vs before treatment</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Statistically significant reduction (P &lt;0.05) of plasma levels of IL-6 (expressed as pg/mL) and TNF-alpha (expressed as pg/mL), 7 and 14 days after the start of treatment with hyperimmune plasma vs the same patients before the beginning of the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>plasma-hyperimmune</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>plasma hyperimmune</intervention_name>
    <description>patients will receive this as add on therapy</description>
    <arm_group_label>plasma-hyperimmune</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <description>patients will receive only standard therapy for Covid-19 infection</description>
    <arm_group_label>plasma-hyperimmune</arm_group_label>
    <arm_group_label>standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inclusion criteria for donors: null-gravid, with a negative history of transfusion of
             blood components; possibility to sign the informed consent

          -  inclusion criteria for Covid-19 infected patients: serious Covid-19 infection,
             possibility to sign the informed consent (also through the legal tutor)

        Exclusion Criteria:

          -  exclusion criteria for donors: presence of pregnancy, recent history of transfusion of
             blood components, &lt; 18 years.

          -  exclusion criteria for Covid-19 infected patients: non serious Covid-19 infection,
             impossibility to sign the informed consent (also through the legal tutor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriella Talarico, MD</last_name>
    <phone>0961883111</phone>
    <email>trasfusionale@aocz.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Longhini, MD</last_name>
      <phone>0961712111</phone>
      <email>longhini@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Torti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Matera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Dominijanni, MD</last_name>
      <phone>0961883111</phone>
      <email>trasfusionale@aocz.it</email>
    </contact>
    <investigator>
      <last_name>Pasquale Minchella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucio Cosco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Laura Guzzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piero Gangemi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Annunziata</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zinno, MD</last_name>
      <phone>0984 6811</phone>
      <email>f.zinno@aocs.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Provinciale</name>
      <address>
        <city>Crotone</city>
        <zip>88900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Leonardo, MD</last_name>
      <phone>0962924471</phone>
      <email>centro.trasfusionale@asp.crotone.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Trimarchi, MD</last_name>
      <phone>0965 730011</phone>
      <email>atrimarchi@aorc.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Provinciale</name>
      <address>
        <city>Vibo Valentia</city>
        <zip>89900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Grandini, MD</last_name>
      <phone>0963-962111</phone>
      <email>trasfusionale@aspvv.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</url>
    <description>reference 6</description>
  </link>
  <link>
    <url>http://www.iccueducation.org.uk/uploads/2/3/1/0/23109338/sofa_score.pdf</url>
    <description>reference 9</description>
  </link>
  <reference>
    <citation>Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016 Mar;14(2):152-7. doi: 10.2450/2015.0131-15. Epub 2015 Nov 6. Review.</citation>
    <PMID>26674811</PMID>
  </reference>
  <reference>
    <citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.</citation>
    <PMID>32113510</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <results_reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </results_reference>
  <results_reference>
    <citation>Linee Guida Cinesi sulla Gestione di COVID-19 Versione 7Â° Pubblicate in data 3/3/2020 dalla Commissione della Salute Nazionale della R.P.C..</citation>
  </results_reference>
  <results_reference>
    <citation>Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015 Nov 19;4:709. doi: 10.1186/s40064-015-1490-9. eCollection 2015.</citation>
    <PMID>26618098</PMID>
  </results_reference>
  <results_reference>
    <citation>Dean CL, Hooper JW, Dye JM, Zak SE, Koepsell SA, Corash L, Benjamin RJ, Kwilas S, Bonds S, Winkler AM, Kraft CS. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion. 2020 May;60(5):1024-1031. doi: 10.1111/trf.15739. Epub 2020 Mar 4.</citation>
    <PMID>32129478</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>severe Covid-19</keyword>
  <keyword>severe coronavirus-2</keyword>
  <keyword>plasma hyperimmune</keyword>
  <keyword>convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

